Levels of soluble CD30 in cord blood and peripheral blood during childhood are not correlated with the development of atopic disease or a family history of atopy

T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis

The use of immune checkpoint inhibitors (ICIs) targeting the T cell inhibitory pathways has revolutionized cancer treatment. However, ICIs might induce progressive atopic dermatitis (AD) by affecting T cell reactivation. The critical role of T cells in AD pathogenesis is widely known. T cell co-signaling pathways regulate T cell activation, where co-signaling molecules are essential for determining the magnitude of the T cell response to antigens. Given the increasing use of ICIs in cancer treatment, a timely overview of the role of T cell co-signaling molecules in AD is required. In this review, we emphasize the importance of these molecules involved in AD pathogenesis. We also discuss the potential of targeting T cell co-signaling pathways to treat AD and present the unresolved issues and existing limitations. A better understanding of the T cell co-signaling pathways would aid investigation of the mechanism, prognosis evaluation, and treatment of AD.

Selected immunological parameters in clinical evaluation of patients with atopic dermatitis

Introduction

It has been suggested that soluble immune receptors (SIRs) such as sCD25 and sCD30 may serve as potential biomarkers in evaluation of atopic dermatitis (AD). Previous studies clearly indicated that serum levels of interleukin (IL)-13 and total IgE (tIgE) might be potentially useful in the evaluation of patents with AD.

Aim

To evaluate whether serum levels of sCD25 and sCD30 are suitable biomarkers of AD. Moreover, we have decided to estimate the usefulness of tIgE and IL-13 serum level determination in the evaluated population.

Material and methods

A group of 102 AD patients was investigated. Serum concentrations of sCD30, sCD25, IL-13 and tIgE were measured. The clinical phenotype of AD was classified as extrinsic (ADe) or intrinsic (ADi) based on the presence of IgE. Statistical analysis was performed to estimate correlations between obtained results and clinical features of the population such as AD phenotype, age, disease extent and severity.

Results

Extrinsic AD was diagnosed in 71% of patients, while ADi phenotype was observed in 29% of the investigated population. A negative correlation between serum levels of sCD25 and sCD30 and disease severity as well patients’ age was established. Serum levels of IL-13 did not reach the cut-off point set by the manufacturer. A positive correlation between serum levels of total IgE and disease severity and patients’ age was observed.

Conclusions

This paper shows that serum levels of sCD25 and sCD30 as well as tIgE are age dependent. Determination of serum levels of sCD25, sCD30 and IL-13 is not useful in everyday practice.

CD30 on stimulated CD4+ T lymphocytes in newborns regarding atopic heredity

CD30 was initially described as Ki-1 Ag on Reed-Sternberg cells of Hodgkin's lymphoma and its and CD30L(+) expression on T cells in placenta were equally frequent in the atopic and non-atopic women. In this article we present a study of CD30 mean fluorescence intensity (MFI) on CB T CD4(+) cells. We tested the hypothesis that in newborns with atopy family history there is a changed CB T cells response after antigen stimulation comparing with those without atopy family history. The study population consisted of 31 newborn babies (29-breastfed, two non-breastfed) and their mothers. Eleven of them had positive and 20 had negative atopy family history. Performed tests included cord blood, which was a subject to flowcytometry analysis and was cultured for 24 h, cytokine production was measured (IFN- gamma, IL-4 and IL-12). Secondly, we measured total maternal and cord blood IgE levels. We studied CD30 MFI as in our studies in larger group of newborns, CD30 expression on CD4(+) T cells appeared to be very low. MFI of CD4(+) CD30(+) after PHA-stimulation (213.55: range: 41.77-434.51) was significantly increased compared to MFI of CD4(+) CD30(+) before PHA-stimulation (43.63: range 28.67-134.67)(p </= 0.001). Newborns with and without atopy family history were analyzed. We found no difference between MFI of CD4(+) CD30(+) on non-stimulated T cells in non-atopic (43.80: range 28.66-134.66) and atopic (43.30: range 29.12-80.92) (p > 0.05). After PHA stimulation MFI of CD4(+) CD30(+) in non-atopic (273.05 (range: 42.9-434.51) was significantly increased compared with the atopic newborns to MFI of 87.1 (range: 41.78-241.42) (p = 0.00). We have not found any correlation between MFI of CD4(+) CD30(+) and total maternal and total CB IgE levels. The role of CD30 in immunological response needs further research studies.